CRIS Current Research Information System

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.388
AS - Asia 2.315
EU - Europa 1.888
Continente sconosciuto - Info sul continente non disponibili 151
AF - Africa 150
SA - Sud America 125
OC - Oceania 6
Totale 8.023
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.332
VN - Vietnam 693
SG - Singapore 674
CN - Cina 527
GB - Regno Unito 477
SE - Svezia 328
IT - Italia 250
DE - Germania 232
HK - Hong Kong 123
FR - Francia 122
IN - India 114
RU - Federazione Russa 100
BR - Brasile 88
IE - Irlanda 83
NL - Olanda 47
CI - Costa d'Avorio 42
FI - Finlandia 42
ZA - Sudafrica 40
JP - Giappone 39
EE - Estonia 38
UA - Ucraina 38
TG - Togo 33
CA - Canada 30
CH - Svizzera 29
BG - Bulgaria 25
KR - Corea 25
BE - Belgio 24
JO - Giordania 19
BD - Bangladesh 14
NG - Nigeria 14
PH - Filippine 14
AR - Argentina 13
MX - Messico 12
TR - Turchia 11
AT - Austria 10
GR - Grecia 10
EC - Ecuador 9
PL - Polonia 9
TH - Thailandia 9
IR - Iran 8
TW - Taiwan 8
ID - Indonesia 6
IQ - Iraq 6
AU - Australia 5
MA - Marocco 5
PK - Pakistan 5
SA - Arabia Saudita 5
SC - Seychelles 5
CO - Colombia 4
CZ - Repubblica Ceca 4
ES - Italia 4
GT - Guatemala 4
LT - Lituania 4
RO - Romania 4
UZ - Uzbekistan 4
DZ - Algeria 3
EG - Egitto 3
JM - Giamaica 3
LB - Libano 3
NI - Nicaragua 3
PE - Perù 3
BO - Bolivia 2
CL - Cile 2
CR - Costa Rica 2
CY - Cipro 2
ET - Etiopia 2
MY - Malesia 2
OM - Oman 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
DK - Danimarca 1
EU - Europa 1
HR - Croazia 1
KE - Kenya 1
MG - Madagascar 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 7.873
Salva come PNG Salva come JPEG
Città #
Singapore 469
Southend 416
Fairfield 397
Ashburn 346
Chandler 253
Dong Ket 205
Seattle 185
San Jose 183
Woodbridge 168
Houston 161
Cambridge 156
Wilmington 143
Ann Arbor 137
Hong Kong 117
Ho Chi Minh City 112
Hanoi 99
Princeton 92
Santa Clara 91
Dublin 83
Beijing 82
Boardman 55
Lauterbourg 44
Nanjing 44
Abidjan 42
Westminster 42
Hefei 41
Los Angeles 41
New York 40
Bologna 39
Padova 37
Helsinki 36
Tokyo 36
Council Bluffs 33
Lomé 33
Bremen 32
Jinan 32
Berlin 25
Bern 25
Shenyang 25
Sofia 25
Brussels 24
Dallas 22
Frankfurt am Main 22
Milan 21
Saint Petersburg 20
Seoul 20
Amman 19
Buffalo 18
Munich 18
Redondo Beach 16
San Diego 16
Turin 16
Haiphong 14
Abeokuta 13
Chicago 13
Falls Church 13
Da Nang 12
Guangzhou 12
London 12
Changsha 11
Hyderabad 11
Jacksonville 11
Orem 11
Zhengzhou 11
Dearborn 10
Hebei 10
São Paulo 10
Phoenix 9
Tianjin 9
Nanchang 8
Norwalk 8
Redmond 8
Shanghai 8
Brooklyn 7
Florence 7
Hangzhou 7
Mexico City 7
North Bergen 7
Olalla 7
Paris 7
Piscataway 7
Redwood City 7
Biên Hòa 6
Boston 6
Des Moines 6
Fremont 6
Can Tho 5
Columbus 5
Falkenstein 5
Fuzhou 5
Haikou 5
Istanbul 5
Kunming 5
Kyiv 5
Ningbo 5
San Francisco 5
Taiyuan 5
The Dalles 5
Toronto 5
Turku 5
Totale 5.235
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 276
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 265
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 249
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 236
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 232
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 217
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 216
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 194
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 192
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 192
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 188
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 187
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 186
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 183
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 182
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 171
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 169
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 166
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 165
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 164
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 160
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 157
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 143
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 143
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 143
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 143
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 142
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 139
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 136
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 134
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 130
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 127
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 125
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors 125
The CD47 pathway is deregulated in human immune thrombocytopenia 123
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 104
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 101
null 98
null 96
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 95
null 86
Totale 8.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022870 0 36 45 113 87 47 29 46 39 114 169 145
2022/20231.027 109 164 63 144 54 81 31 63 176 42 53 47
2023/2024246 14 42 28 29 20 58 4 10 6 16 8 11
2024/2025904 46 166 82 84 122 37 56 26 25 69 36 155
2025/20262.116 175 149 189 144 212 136 194 147 474 163 61 72
2026/2027119 53 66 0 0 0 0 0 0 0 0 0 0
Totale 8.023